カテゴリー： FactMR, 世界, 医療/バイオ

制酸薬の世界市場2023年-2033年：予測・動向・分析・競争状況

◆英語タイトル：Antacids Market By Drug Class (Proton Pump Inhibitors, H2 Antagonists, Acid Neutralizers), By Formulation (Tablets, Liquid, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region – Global Market Insights 2023 to 2033

FactMRが発行した調査報告書（FACT23MA039）◆商品コード：FACT23MA039
◆発行会社（リサーチ会社）：FactMR
◆発行日：2023年4月12日
◆ページ数：約170
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧、印刷不可）USD4,500 ⇒換算￥684,000見積依頼/購入/質問フォーム
Global Site License（同一拠点内共有可）USD8,500 ⇒換算￥1,292,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Fact.MR社の本市場調査資料では、世界の制酸薬市場を徹底的に調査・分析し、予測期間中（2023年〜2033年）の動向を展望しています。本書は、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、薬物クラス別（プロトンポンプ阻害剤、H2アンタゴニスト、酸性中和剤）分析、製剤別（錠剤、液体、粉末、その他）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、競争状況など、以下の構成でまとめています。なお、主な市場参入企業として、 Bayer AG、Boehringer Ingelheim GmbH、Dr. Reddy’s Laboratories Ltd.などの情報を含んでいます。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・世界の制酸薬市場規模：薬物クラス別
- プロトンポンプ阻害剤の市場規模
- H2アンタゴニストの市場規模
- 酸性中和剤の市場規模
・世界の制酸薬市場規模：製剤別
- 錠剤型制酸薬の市場規模
- 液体型制酸薬の市場規模
- 粉末型制酸薬の市場規模
- その他製剤の市場規模
・世界の制酸薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- その他チャネルの市場規模
・世界の制酸薬市場規模：地域別
- 北米の制酸薬市場規模
- 中南米の制酸薬市場規模
- ヨーロッパの制酸薬市場規模
- アジア太平洋の制酸薬市場規模
- 中東・アフリカの制酸薬市場規模
・競争状況

本資料には、各企業の製品ポートフォリオや主要戦略、包括的なSWOT分析などの要素を含む企業情報を含んでいます。企業のプレゼンスは、すべての主要プレーヤーについてマッピングされ、マトリックスを通して提供されます。これにより、読者に実用的な洞察を提示し、熟考して市場の状況を提供し、制酸薬における競争レベルを推測するのに役立ちます。

ANTACIDS Market – Scope of Report

A recent study by Fact.MR on the ANTACIDS market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering Antacids.
The study also provides the dynamics responsible for influencing the future status of the ANTACIDS market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the ANTACIDS market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of ANTACIDS across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of ANTACIDS during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for ANTACIDS are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global ANTACIDS market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the ANTACIDS market during the forecast period.
Country-specific valuation on demand for ANTACIDS has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of XYZ, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering ANTACIDS has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the ANTACIDS domain.

❖ レポートの目次 ❖

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity

    4.4. Global Market Value (US$ Mn) Forecast, 2023 – 2033

    4.5. Porter’s Five Force Analysis

    4.6. Value Chain Analysis

    4.7. Market Outlook

5. Global Market Analysis and Forecasts, By Drug Class

    5.1. Introduction & Definition

    5.2. Key Findings / Developments

    5.3. Key Trends

    5.4. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033

        5.4.1. Proton pump inhibitors

        5.4.2. H2 Antagonist

        5.4.3. Acid neutralizers

    5.5. Market Attractiveness By Drug Class

6. Global Market Analysis and Forecasts, By Formulation

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Key Trends

    6.4. Market Value (US$ Mn) Forecast By Formulation, 2023-2033

        6.4.1. Tablet

        6.4.2. Liquid

        6.4.3. Powder

        6.4.4. Others

    6.5. Market Attractiveness By Formulation

7. Global Market Analysis and Forecasts, By Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Key Trends

    7.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033

        7.4.1. Hospital Pharmacies

        7.4.2. Retail Pharmacies

        7.4.3. Others

    7.5. Market Attractiveness By Distribution Channel

8. Global Market Analysis and Forecasts, By Region

    8.1. Key Findings

    8.2. Market Value (US$ Mn) Forecast By Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East and Africa

    8.3. Market Attractiveness By Country/Region

9. North America Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

        9.1.2. Key Trends

    9.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033

        9.2.1. Proton pump inhibitors

        9.2.2. H2 Antagonist

        9.2.3. Acid neutralizers

    9.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033

        9.3.1. Tablet

        9.3.2. Liquid

        9.3.3. Powder

        9.3.4. Others

    9.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033

        9.4.1. Hospital Pharmacies

        9.4.2. Retail Pharmacies

        9.4.3. Others

    9.5. Market Value (US$ Mn) Forecast By Country, 2023-2033

        9.5.1. U.S.

        9.5.2. Canada

    9.6. Market Attractiveness Analysis

        9.6.1. By Drug Class

        9.6.2. By Formulation

        9.6.3. By Distribution Channel

        9.6.4. By Country

10. Europe Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

        10.1.2. Key Trends

    10.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033

        10.2.1. Proton pump inhibitors

        10.2.2. H2 Antagonist

        10.2.3. Acid neutralizers

    10.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033

        10.3.1. Tablet

        10.3.2. Liquid

        10.3.3. Powder

        10.3.4. Others

    10.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Others

    10.5. Market Value (US$ Mn) Forecast By Country, 2023-2033

        10.5.1. U.K.

        10.5.2. Germany

        10.5.3. France

        10.5.4. Spain

        10.5.5. Italy

        10.5.6. Rest of Europe

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Formulation

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Asia Pacific Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

        11.1.2. Key Trends

    11.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033

        11.2.1. Proton pump inhibitors

        11.2.2. H2 Antagonist

        11.2.3. Acid neutralizers

    11.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033

        11.3.1. Tablet

        11.3.2. Liquid

        11.3.3. Powder

        11.3.4. Others

    11.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Others

    11.5. Market Value (US$ Mn) Forecast By Country, 2023-2033

        11.5.1. India

        11.5.2. China

        11.5.3. Japan

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Aisa Pacific

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Formulation

        11.6.3. By Distribution Channel

        11.6.4. By Country

12. Latin America Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

        12.1.2. Key Trends

    12.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033

        12.2.1. Proton pump inhibitors

        12.2.2. H2 Antagonist

        12.2.3. Acid neutralizers

    12.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033

        12.3.1. Tablet

        12.3.2. Liquid

        12.3.3. Powder

        12.3.4. Others

    12.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Others

    12.5. Market Value (US$ Mn) Forecast By Country, 2023-2033

        12.5.1. Brazil

        12.5.2. Mexico

        12.5.3. Rest of Latin America

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Formulation

        12.6.3. By Distribution Channel

        12.6.4. By Country

13. Middle East and Africa Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

        13.1.2. Key Trends

    13.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033

        13.2.1. Proton pump inhibitors

        13.2.2. H2 Antagonist

        13.2.3. Acid neutralizers

    13.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033

        13.3.1. Tablet

        13.3.2. Liquid

        13.3.3. Powder

        13.3.4. Others

    13.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Others

    13.5. Market Value (US$ Mn) Forecast By Country, 2023-2033

        13.5.1. South Africa

        13.5.2. Saudi Arabia

        13.5.3. Rest of MEA

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Formulation

        13.6.3. By Distribution Channel

        13.6.4. By Country

14. Competition Landscape

    14.1. Market Players

    14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

        14.2.1. AstraZeneca

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Business Overview

            14.2.1.3. Product Portfolio

            14.2.1.4. Financial Overview

            14.2.1.5. SWOT Analysis

            14.2.1.6. Strategic overview

        14.2.2. Bayer AG

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Business Overview

            14.2.2.3. Product Portfolio

            14.2.2.4. Financial Overview

            14.2.2.5. SWOT Analysis

            14.2.2.6. Strategic overview

        14.2.3. Boehringer Ingelheim GmbH

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.3.2. Business Overview

            14.2.3.3. Product Portfolio

            14.2.3.4. Financial Overview

            14.2.3.5. SWOT Analysis

            14.2.3.6. Strategic overview

        14.2.4. Dr. Reddy’s Laboratories Ltd.

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.4.2. Business Overview

            14.2.4.3. Product Portfolio

            14.2.4.4. Financial Overview

            14.2.4.5. SWOT Analysis

            14.2.4.6. Strategic overview

        14.2.5. GlaxoSmithKline plc

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.5.2. Business Overview

            14.2.5.3. Product Portfolio

            14.2.5.4. Financial Overview

            14.2.5.5. SWOT Analysis

            14.2.5.6. Strategic overview

        14.2.6. Johnson & Johnson

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.6.2. Business Overview

            14.2.6.3. Product Portfolio

            14.2.6.4. Financial Overview

            14.2.6.5. SWOT Analysis

            14.2.6.6. Strategic overview

        14.2.7. Pfizer Inc.

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.7.2. Business Overview

            14.2.7.3. Product Portfolio

            14.2.7.4. Financial Overview

            14.2.7.5. SWOT Analysis

            14.2.7.6. Strategic overview

        14.2.8. Procter & Gamble

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.8.2. Business Overview

            14.2.8.3. Product Portfolio

            14.2.8.4. Financial Overview

            14.2.8.5. SWOT Analysis

            14.2.8.6. Strategic overview

        14.2.9. Reckitt Benckiser Group plc

            14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.9.2. Business Overview

            14.2.9.3. Product Portfolio

            14.2.9.4. Financial Overview

            14.2.9.5. SWOT Analysis

            14.2.9.6. Strategic overview

        14.2.10. Sanofi

            14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.10.2. Business Overview

            14.2.10.3. Product Portfolio

            14.2.10.4. Financial Overview

            14.2.10.5. SWOT Analysis

            14.2.10.6. Strategic overview

        14.2.11. Sun Pharmaceuticals Ltd

            14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.11.2. Business Overview

            14.2.11.3. Product Portfolio

            14.2.11.4. Financial Overview

            14.2.11.5. SWOT Analysis

            14.2.11.6. Strategic overview

        14.2.12. Takeda Pharmaceutical

            14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.12.2. Business Overview

            14.2.12.3. Product Portfolio

            14.2.12.4. Financial Overview

            14.2.12.5. SWOT Analysis

            14.2.12.6. Strategic overview

        14.2.13. Valeant Pharmaceuticals International, Inc.

            14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.13.2. Business Overview

            14.2.13.3. Product Portfolio

            14.2.13.4. Financial Overview

            14.2.13.5. SWOT Analysis

            14.2.13.6. Strategic overview



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 制酸薬の世界市場2023年-2033年：予測・動向・分析・競争状況(Antacids Market By Drug Class (Proton Pump Inhibitors, H2 Antagonists, Acid Neutralizers), By Formulation (Tablets, Liquid, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region – Global Market Insights 2023 to 2033)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ペプチド感染症治療薬の世界市場2023年～2033年：予測・動向・分析・競争状況
  • 大発作治療の世界市場2023年-2033年：予測・動向・分析・競争状況
  • ペプチドベース心臓血管治療薬の世界市場2023年-2033年：予測・動向・分析・競争状況
  • 低電圧モーターの世界市場2023年-2033年：予測・動向・分析・競争状況
  • ペプチド治療薬（メタボリックシンドローム用）の世界市場2023年～2033年：予測・動向・分析・競争状況

    • ◆H&Iグローバルリサーチのお客様（例）◆